Online First

Review Article
Optimizing Blood Stem Cell Transplants Through Cellular Engineering
Krystal Valerie Qian Ying Soh1,4, William Ying Khee Hwang1,2,3

1National Cancer Centre Singapore, Singapore, SG 169610

2Singapore General Hospital, Singapore, SG

3Duke-NUS Medical School Singapore, Singapore, SG

4Yong Loo Lin School of Medicine, National University of Singapore, Singapore, SG

hematopoietic stem cell transplants, haematopoietic stem and progenitor cell expansion, cell selection in haploidentical transplantation, immune regulatory cells, immune effector cell therapy
Submitted:June 21, 2021
Accepted:August 11, 2021
Published online:January 14, 2022


Haematopoietic stem cell transplants (HSCT) are used in the treatment of blood cancers, autoimmune diseases, and metabolic disorders. Over 1.5 million transplants have been performed around the world thus far. In an attempt to enhance the efficacy of the cells used for transplantation, efforts are underway to use cellular engineering to increase cell numbers through: (1) the expansion of hematopoietic stem and progenitor cells (HSPC); (2) cellular subset selection to remove cells that cause graft-versus-host disease (GvHD), while adding back cells, which can mediate anti-tumor and anti-viral immunity; (3) the use of immune regulatory cells, such as mesenchymal stromal cells (MSC) and regulatory T cells (Tregs) to control GvHD; (4) the use of immune effector cells to mount immunological control of tumor cells before, after, or independent of blood stem cell transplants.



Online ISSN:2432-7026